Physician profile
Mark J Roy
NPI 1851360424
$4,670.53
in general payments reported to CMS, 2019-2025
19 companies · $973 in 2025
The $973 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $299 · 2021: $408 · 2022: $782 · 2023: $863 · 2024: $847 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,524 · Entertainment: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,523.55 |
| Entertainment | $158.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $810.94 | 2019-2025 | Clareon Panoptix Pro, Hydrus Microstent, Precision7 |
| Glaukos Corporation | $589.50 | 2021-2024 | Idose |
| Abbvie INC. | $558.17 | 2022-2025 | |
| Dompe US, INC. | $368.39 | 2023-2024 | Oxervate |
| Allergan, INC. | $328.81 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $290.83 | 2024-2025 | Xdemvy |
| Carl Zeiss Meditec USA, INC. | $279.39 | 2023 | Cirrus Hd-Oct, Clarus |
| Bausch & Lomb Americas INC. | $241.49 | 2024-2025 | Miebo, Xiidra |
| Oyster Point Pharma, INC. | $205.18 | 2022-2023 | Tyrvaya |
| Optos, INC. | $158.74 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $155.62 | 2022-2024 | Clariti Contact Lens |
| Lkc Technologies, INC. | $153.13 | 2025 | |
| Biotissue Holdings INC. | $133.52 | 2023 | |
| Shire North American Group INC | $123.45 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $116.53 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $72.14 | 2024-2025 | Tobradex St, Iheezo, Natacyn |
| Sun Pharmaceutical Industries INC. | $37.14 | 2023 | Cequa |
| Ocular Therapeutix, INC. | $28.84 | 2023 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.